
    
      In primary unilateral total knee arthroplasty patients, The investigator will examine the
      effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months
      pre-op and continued for a total of 15 months. This will be compared to osteopenic patients
      receiving no therapy as well as previously published values in untreated osteoporotic
      patients 12 months following Total Knee Arthroplasty (TKA).
    
  